If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

Share Price is delayed by 15 minutes
Get Live Data
745.50    -8.00 (-1.06%)
Bid:
745.00
Ask:
746.00
Spread: 1.00 (0.134%)
Market Cap: £2.51b
DRX Live PriceLast checked at - London Stock Exchange

Intraday Drax Share Chart

2022 Performance Awards - EPS Condition

19 Apr 2022 12:00

RNS Number : 5995I
Drax Group PLC
19 April 2022
 

19 April 2022

Drax Group plc

("Drax" or the "Group"; Symbol:DRX)

 

2022 Performance Awards - EPS Condition

At the time of publishing the annual report for the financial year ended 31 December 2021, Drax advised it would be separately determining, and thereafter releasing details of, the Cumulative Adjusted Earnings per Share performance condition which applies to grants made to PDMRs and other employees in the 2022 financial year.

The vesting of awards granted are subject to satisfying two performance criteria over the financial years 2022, 2023 and 2024. 50% of the awards will be measured based on Relative Total Shareholder Return relative to the FTSE-350, and the remaining 50% will be measured based on Cumulative Adjusted Earnings per Share.

Following a meeting of the Remuneration Committee, the proposed Cumulative Adjusted EPS target for 2022 has been agreed. The EPS target was set after considering the company's internal forecasts, market expectations and sector peers.

 

 

Threshold

Target

Maximum

239.5p

266.1p

292.7p

 

 

BASIS OF VESTING

Performance

Target

% of Award Vesting(of EPS performance condition)

Below threshold

0%

Threshold

239.5p

25%

Maximum

292.7p

100%

 

Vesting between the threshold and maximum will be on a straight-line basis.

The EPS target is 'Adjusted EPS', derived from Adjusted Results as reported in the Company's audited financial statements. Instances where such adjustments might apply include acquisition and restructuring costs, asset obsolescence charges and certain remeasurements on derivative contracts.

There may arise circumstances during the performance period where adjustment or discretion is applied by the Remuneration Committee by reference to exceptional items and the Remuneration Policy. The application of such adjustments would be considered during and upon completion of the performance cycle. In making their assessment, the Remuneration Committee will take into account appropriate advice (for example from our auditors, Remuneration Committee advisers or the Audit Committee) and also give due consideration to the shareholder experience. The Remuneration Committee would also take into account exceptional and unforeseen circumstances, including wider considerations such as the prevailing market environment, in assessing the appropriate level of vesting judged against the performance of the Company and management at the end of the performance period.

Total Shareholder Return relative to the FTSE-350 will be measured over the three-year period (2022-2024) consistent with the approach previously approved by shareholders.

The Remuneration Committee of Drax considers that attaining outturn at the top end of the range would represent strong performance considering the uncertain economic circumstances and the challenges to the broader economy. 

 

Ends

 

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com 

+44 (0) 7730 763 949

Brett Gladden, Group Company Secretarybrett.gladden@drax.com+44 (0)7936 362586

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFSUEESEEL
Date   Source Headline
28th Nov 20245:33 pmRNSTransaction in Own Shares
27th Nov 20245:49 pmRNSTransaction in Own Shares
26th Nov 20245:42 pmRNSTransaction in Own Shares
25th Nov 20246:01 pmRNSTransaction in Own Shares
22nd Nov 20245:51 pmRNSTransaction in Own Shares
21st Nov 20246:23 pmRNSTransaction in Own Shares
20th Nov 20246:10 pmRNSTransaction in Own Shares
19th Nov 20245:51 pmRNSTransaction in Own Shares
18th Nov 20245:55 pmRNSTransaction in Own Shares
15th Nov 20245:45 pmRNSTransaction in Own Shares
14th Nov 20245:39 pmRNSTransaction in Own Shares
13th Nov 20246:20 pmRNSTransaction in Own Shares
12th Nov 20246:16 pmRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTrading Update
11th Nov 20245:39 pmRNSTransaction in Own Shares
8th Nov 20246:23 pmRNSTransaction in Own Shares
6th Nov 20245:53 pmRNSTransaction in Own Shares
5th Nov 20245:56 pmRNSTransaction in Own Shares
4th Nov 20245:42 pmRNSTransaction in Own Shares
4th Nov 202411:49 amRNSTotal Voting Rights
1st Nov 20245:34 pmRNSTransaction in Own Shares
31st Oct 20245:37 pmRNSTransaction in Own Shares
30th Oct 20245:31 pmRNSTransaction in Own Shares
29th Oct 20245:50 pmRNSTransaction in Own Shares
28th Oct 20245:28 pmRNSTransaction in Own Shares
25th Oct 20245:22 pmRNSTransaction in Own Shares
25th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNSTransaction in Own Shares
22nd Oct 20246:27 pmRNSTransaction in Own Shares
22nd Oct 20247:00 amRNSShare Buyback Programme
21st Oct 20245:50 pmRNSTransaction in Own Shares
21st Oct 20243:30 pmRNSDirector/PDMR Shareholding
18th Oct 20245:54 pmRNSTransaction in Own Shares
18th Oct 20247:00 amRNSTransaction in Own Shares
17th Oct 20247:00 amRNSTransaction in Own Shares
16th Oct 20247:00 amRNSTransaction in Own Shares
15th Oct 20247:00 amRNSTransaction in Own Shares
11th Oct 20246:20 pmRNSTransaction in Own Shares
10th Oct 20245:34 pmRNSTransaction in Own Shares
9th Oct 20245:43 pmRNSTransaction in Own Shares
8th Oct 20245:46 pmRNSTransaction in Own Shares
7th Oct 20245:43 pmRNSTransaction in Own Shares
7th Oct 20248:45 amRNSAdditional Listing
7th Oct 20247:00 amRNSTransaction in Own Shares
3rd Oct 20245:35 pmRNSTransaction in Own Shares
2nd Oct 20245:47 pmRNSTransaction in Own Shares
1st Oct 20246:12 pmRNSTransaction in Own Shares
1st Oct 202412:49 pmRNSNotice of Change to Director Details
1st Oct 20249:47 amRNSBlock listing Interim Review
1st Oct 20249:45 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.